Common Contracts
2 similar Investment Banking Engagement Agreement contracts by Bio-Matrix Scientific Group, Inc., Regen BioPharma Inc
July 1, 2016 David Koos Chairman & CEO Regen BioPharma Inc. (RGBP) La Mesa, CA 91942 Delivered: 07/01/2016 Via email to: David Koos david.koos@regenbiopharma.com Dear David,Investment Banking Engagement Agreement • July 7th, 2016 • Bio-Matrix Scientific Group, Inc. • Services-business services, nec
The purpose of this investment banking engagement agreement (the "Agreement") is to set forth the terms and conditions pursuant to which CIM Securities, LLC ("CIM"), a FINRA member in good standing, shall act as exclusive financial advisor and placement agent for Regen BioPharma Inc. (RGBP, RGBPP) (“Company”), a Nevada Corporation and all affiliates (also the "Company") and introduce the Company to one or more accredited investors (“Investors”) in connection to a proposed private placement (the "Private Placement") of equity and / or debt securities (the "Securities") of the Company for the capital needed to continue research and development on four blocker compounds. However, CIM specifically acknowledges that the Company has retained Objective Capital Partners, located in San Diego, California, to identify potential strategic partners for the Company, which could result in an infusion of capital that does not involve the sale of debt or equity securities. The gross proceeds from the
July 1, 2016 David Koos Chairman & CEO Regen BioPharma Inc. (RGBP) La Mesa, CA 91942 Delivered: 07/01/2016 Via email to: David Koos david.koos@regenbiopharma.com Dear David,Investment Banking Engagement Agreement • July 7th, 2016 • Regen BioPharma Inc • Pharmaceutical preparations
The purpose of this investment banking engagement agreement (the "Agreement") is to set forth the terms and conditions pursuant to which CIM Securities, LLC ("CIM"), a FINRA member in good standing, shall act as exclusive financial advisor and placement agent for Regen BioPharma Inc. (RGBP, RGBPP) (“Company”), a Nevada Corporation and all affiliates (also the "Company") and introduce the Company to one or more accredited investors (“Investors”) in connection to a proposed private placement (the "Private Placement") of equity and / or debt securities (the "Securities") of the Company for the capital needed to continue research and development on four blocker compounds. However, CIM specifically acknowledges that the Company has retained Objective Capital Partners, located in San Diego, California, to identify potential strategic partners for the Company, which could result in an infusion of capital that does not involve the sale of debt or equity securities. The gross proceeds from the
